首页> 外文期刊>Future medicinal chemistry >New pyrrolopyridine-based thiazolotriazoles as diabetics inhibitors: enzymatic kinetics and in silico study
【24h】

New pyrrolopyridine-based thiazolotriazoles as diabetics inhibitors: enzymatic kinetics and in silico study

机译:New pyrrolopyridine-based thiazolotriazoles as diabetics inhibitors: enzymatic kinetics and in silico study

获取原文
获取原文并翻译 | 示例
           

摘要

Aim: To synthesize pyrrolopyridine-based thiazolotriazoles as a novel class of alpha-amylase and alpha-glucosidase inhibitors and to determine their enzymatic kinetics. Methodology: Pyrrolopyridine-based thiazolotriazole analogs (1-24) were synthesized and characterized through proton nuclear magnetic resonance, carbon-13 nuclear magnetic resonance and high-resolution electron ionization mass spectrometry. Results: All synthesized analogs displayed good inhibitory potential of alpha-amylase and alpha-glucosidase ranging 17.65-70.7 mu M and 18.15-71.97 mu M, respectively, compared with the reference drug, acarbose (11.98 mu M and 12.79 mu M). Analog 3 was the most potent among the synthesized analogs, having alpha-amylase and alpha-glucosidase inhibitory activity at 17.65 and 18.15 mu M, respectively. The structure-activity relationship and binding modes of interactions between selected analogs were confirmed via docking and enzymatic kinetics studies. The compounds (1-24) were tested for cytotoxicity against the 3T3 mouse fibroblast cell line and were observed to be nontoxic.

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号